BioMotiv
Accelerating Breakthrough Discoveries into Medicines

Mike Lark

Mike Lark, PhD

Mick Hunter.png

Dr. Lark, BioMotiv Project Leader, has over 30 years of experience at leading and managing drug discovery and development teams at both large pharmaceutical and small biotech companies.

Prior to joining BioMotiv, he was CSO and Sr. Vice President of Research at Trevena Inc., where he was a member of the executive team and was responsible for the drug discovery and non-clinical development functions within the company.  Prior to Trevena, Dr. Lark was Vice President of Biology at Centocor R&D where he was responsible for the therapeutic discovery strategy and execution in immunology, oncology, tissue remodeling and biomarkers, and Director of Musculoskeletal Diseases at GlaxoSmithKline, where he managed a portfolio of drug discovery projects targeting osteoporosis, osteoarthritis, rheumatoid arthritis and psoriasis. Dr. Lark started his industry career as a Senior Investigator at Merck Research laboratories, where he led a drug discovery team targeting matrix metalloproteinase-3 for the treatment of osteoarthritis. He has published over 130 peer reviewed papers, reviews and book chapters and is a co-inventor on 11 patents.

Dr. Lark received his B.S. in Microbiology from the Pennsylvania State University and his Ph.D. in Molecular Biology and Microbiology from the Case Western Reserve University Medical School. He completed a postdoctoral fellowship in the Department of Pathology at The University of Washington.